"AUROPHARMA: Injecting Growth – From Supports to Stratospheric Gains."

Stock Outlook:

Aurobindo Pharma exhibited robust intraday buying on December 18, 2025, opening at ₹1190, hitting high ₹1213.70 (+2%), low ₹1176.60 (-1.15%), and closing at ₹1209.30 (+1.37%) with 947k volume (1.4x 20D avg) and 52% delivery, signaling strong hands interest amid pharma rebound. Detailed technicals reveal strong buy oscillators overriding bearish MAs, supported by Q2 FY26 revenue growth to ₹8286 Cr despite FDA procedural observations. Fundamentals underscore value at P/E 20.52 (sector low), low debt, and injectables expansion potential. Auropharma Positive & Negative Points: Price/Volume: +1.37% gain with 52% delivery and 1.4x volume breakout above R1; countered by YTD -3.2% lag, trading below 52W high ₹1356 near MA20. Technicals: 6/8 oscillators signal buy with pivot ₹1202 hold; offset by 9/12 MAs sell and negative MACD. Financials: Low P/E 20.5, +6% revenue, minimal debt shine; EBITDA margin dipped -101 bps with EPS -4% YoY. Operations: Injectables/CDMO growth and Europe +12% boost prospects; US FDA Form 483 (5 procedural obs) adds caution. Buying Reason, News & Impact: Today's Surge: Pharma index +0.8% rebound, high delivery amid Q2 momentum carryover (PAT beat estimates), short-covering post-FDA dip. No specific Dec 18 trigger; sector rotation from IT to pharma on global cues. Key News/Event: US FDA inspected APL Healthcare Unit-IV (Dec 8-17, 2025): 5 procedural observations (no data integrity issues)—company filing response by Jan 2026; historical procedural fixes resolved quickly, minimal impact (stock -2% post-news, recovered). Positive: Injectables bet, FY26 guidance 12-14% revenue growth. Impact: Neutral-short term (regulatory overhang caps), bullish medium-term on diversification.